Alzheimer's Drug Approved by Health Canada
Lecanemab, a lab-made antibody, aims to slow the early stages of Alzheimer's disease by targeting plaques in the brain.
According to the Alzheimer Society of Canada, lecanemab is the first disease-modifying Alzheimer's treatment approved for use in the country.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The conditional approval of lecanemab is being called a positive development for those diagnosed with dementia, who fear losing independence.
Lecanemab is administered via intravenous infusion and targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Author's summary: Lecanemab approved to slow early Alzheimer's.
More News
- Editorial: Movable bike barrier a good step for Richmond Bridge
- Israel massacres 100 Palestinians in a single day in Gaza
- The data roles you need underpinning AI
- Core Scientific shareholders dismiss $9B CoreWeave deal over valuation worries - SiliconANGLE
- 12 A-List Actors Who Got Their Start in Horror Movies